Federal task force returns to bolster vaccine safety science—bringing renewed oversight and expertise to childhood immunization policies. Photo by SHVETS production via Pexels

Two-Year Gift: FDA Approves Tzield for Youngest Type 1 Diabetes Patients, Ages 1 and Older—First Disease-Modifying Therapy Breakthrough

FDA Approves Tzield for Children Ages 1+ With Stage 2 Type 1 Diabetes | KarmActive ✓ FDA Approval Expanded to Children Ages 1+ FDA Approves Tzield for Children Ages 1+ With Stage 2 Type 1 Diabetes First disease-modifying therapy approved to delay disease progression in the youngest patients The U.S. Food and Drug Administration approved an expanded indication for Tzield (teplizumab-mzwv) to delay the progression from stage 2 to stage 3 type

Read More >>
Health/News/USA
8 mins read

Most Read

Artist Representation

SBTi Trend Tracker 2025: 40% Surge in Climate Targets, 239 Companies Cut, and Asia Leads the Charge

SBTi Trend Tracker 2025: Corporate Climate Targets Hit 10,000 Milestone Climate Finance Corporate Climate Targets Hit 10,000 — Asia Is Now Driving the Surge The SBTi Trend Tracker 2025 confirms a 40% jump in validated science-based targets. Here’s what the data says, where the growth is coming from, and how investors in Singapore can read

Keep Reading →